Rob Hunter has over twenty-four years of experience in both human and veterinary drug development and drug development strategy with a wide range of companies large and small. He has contributed to the approval of numerous FDA and EPA products in the animal health sector that includes brands such Dectomax, Doxidyl, Revolution, Kexxtone, Micotil, Ovugel, Posilac, Experior, Pulmotil, Optaflex, and Tylan. He is a subject matter expert in antimicrobials, pharmacokinetics/pharmacodynamics (PK/PD), interspecies allometry, drug metabolism, bioequivalency (BE), and tissue residues affecting human food safety.. He has presided over several Animal Health Institute (AHI) committees and the Veterinary International Conference on Harmonization (VICH) on the bioequivalence expert committee.
Rob has previously worked for Pfizer Animal Health, Elanco, Parnell, and Provetica. He has also held various teaching positions with Kansas State University and the University of Kansas.
Rob holds a Doctorate of Philosophy in Veterinary Pharmacology from Louisiana State University, a Master’s Degree in Veterinary Physiology from Texas A&M University, and a Bachelor’s in Animal Science from Angelo State University in San Angelo, Texas.